New hope for dialysis patients: drug trial aims to improve treatment
NCT ID NCT07491042
Summary
This study is testing whether a medication called dapagliflozin can help people with end-stage kidney failure who use peritoneal dialysis. Researchers want to see if taking the drug for six months improves how well fluid is removed during dialysis and helps preserve remaining kidney function. The trial will include about 30 patients who are already on long-term peritoneal dialysis.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE CHRONIC RENAL FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jehad Badawi AL LAHAM
RECRUITINGNizwá, Oman
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.